Your browser doesn't support javascript.
loading
Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing.
Trabucco, Sally E; Sokol, Ethan S; Maund, Sophia L; Moore, Jay A; Frampton, Garrett M; Albacker, Lee A; Oestergaard, Mikkel Z; Venstrom, Jeffrey; Sehn, Laurie H; Bolen, Christopher R.
Afiliación
  • Trabucco SE; Foundation Medicine, Inc., Cambridge MA 02141, USA.
  • Sokol ES; Foundation Medicine, Inc., Cambridge MA 02141, USA.
  • Maund SL; Genentech, Inc., South San Francisco, CA 94080, USA.
  • Moore JA; Foundation Medicine, Inc., Cambridge MA 02141, USA.
  • Frampton GM; Foundation Medicine, Inc., Cambridge MA 02141, USA.
  • Albacker LA; Foundation Medicine, Inc., Cambridge MA 02141, USA.
  • Oestergaard MZ; F. Hoffmann-La Roche Ltd., Basel, 4070, Switzerland.
  • Venstrom J; Foundation Medicine, Inc., Cambridge MA 02141, USA.
  • Sehn LH; BC Cancer Centre for Lymphoid Cancer & University of British Columbia, Vancouver, BC, V5Z 1L3, Canada.
  • Bolen CR; Genentech, Inc., South San Francisco, CA 94080, USA.
Future Oncol ; 17(31): 4171-4183, 2021 Nov.
Article en En | MEDLINE | ID: mdl-34313135
Lay abstract To determine subtypes of diffuse large B-cell lymphoma (DLBCL), a cancer with poor survival, we aimed to identify DLBCL subtypes using DNA mutation-based tools. A targeted gene-sequencing platform, which measures the number and types of DNA mutations in a sample, was used to categorize DLBCL subtypes. Two major patterns of mutations associated with subtypes were identified: Catalogue of Somatic Mutations in Cancer (COSMIC) signature 23 and COSMIC signature 3. Differences in how the subtypes developed suggest a link between tumor developments and B cells being activated normally, confirming where the DLBCL subtypes came from. Combining this information with comprehensive genomic profiling, which determines all of the genes that a person has, allowed identification of features that are associated with DLBCL subtypes and showed that a DLBCL subtype can be determined without using RNA.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Secuenciación de Nucleótidos de Alto Rendimiento Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Future Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Secuenciación de Nucleótidos de Alto Rendimiento Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Future Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido